---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-011546"
form_type: "8-K"
ticker: "INCY"
cik: "0000879169"
company_name: "INCYTE CORP"
filed_at: "2022-08-02T23:59:59+00:00"
generated_at: "2026-06-24T06:12:30.443023+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Incyte Q2 total revenues up 29% to $911M; raises Jakafi guidance bottom end

## Summary
- Total revenues $911M (+29% YoY); product revenues $664M (+15% YoY).
- Jakafi net product revenues $598M (+13% YoY); FY guidance raised to $2.36-$2.40B.
- GAAP diluted EPS $0.72; Non-GAAP diluted EPS $1.01 (up from $0.80 YoY).
- Opzelura approved for vitiligo in July; ~48,000 units shipped in Q2 in atopic dermatitis launch.
- Itacitinib development in chronic GVHD halted; pivotal trial deemed unlikely to succeed.

## SEC filing metadata
- accession: 0001558370-22-011546
- form_type: 8-K
- ticker: INCY
- cik: 0000879169
- company_name: INCYTE CORP
- filed_at: 2022-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879169/000155837022011546/0001558370-22-011546-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879169/000155837022011546/incy-20220802x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-011546
- JSON: https://secwatch.observer/filing/0001558370-22-011546.json
- Plain text: https://secwatch.observer/filing/0001558370-22-011546.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.